

Stroke risk stratification in hypertrophic cardiomyopathy

Zhang, Juqian; Potpara, Tatjana; Lip, Gregory Yh

Published in:
Hellenic Journal of Cardiology

DOI (link to publication from Publisher):
[10.1016/j.hjc.2020.11.003](https://doi.org/10.1016/j.hjc.2020.11.003)

Creative Commons License
CC BY-NC-ND 4.0

Publication date:
2020

Document Version
Publisher's PDF, also known as Version of record

[Link to publication from Aalborg University](#)

Citation for published version (APA):
Zhang, J., Potpara, T., & Lip, G. Y. (2020). Stroke risk stratification in hypertrophic cardiomyopathy. *Hellenic Journal of Cardiology*, 61(5), 318-320. <https://doi.org/10.1016/j.hjc.2020.11.003>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal -

Take down policy

If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to the work immediately and investigate your claim.



Contents lists available at ScienceDirect

Hellenic Journal of Cardiology

journal homepage: <http://www.journals.elsevier.com/hellenic-journal-of-cardiology/>

Editorial

Stroke risk stratification in hypertrophic cardiomyopathy



Hypertrophic cardiomyopathy (HCM), a common inherited cardiac disease, is defined by the presence of left ventricular (LV) wall thickness which is not solely explained by abnormal loading conditions.¹ The prevalence of HCM is 1 in 500 in most studies, but using combined clinical parameters and genetic carriers, HCM could affect 1 in 200.² Patients with HCM have excess mortality compared with general population,³ the pooled 5- and 10-year survival rate of HCM is 82.2% and 75%, respectively.⁴ Sudden cardiac death, heart failure and stroke are the major mortality risks with thromboembolic events occurring in 1 to 4 per 100 person-years.^{5–11} Population-based cohorts observed progressively increased incidence of stroke among HCM patients following their diagnosis.^{12,13} Prompt risk stratification for thromboembolism is thereby of great importance.

Atrial fibrillation (AF) is the most common cardiac arrhythmia in HCM, affecting 20–25% of patients with HCM, with incidence of 2.5% new cases annually.^{6,13–16} In patients with HCM, AF is associated with the pooled 7-fold increase in thromboembolism, 3-fold increase in heart failure, 2.5-fold increased risk of mortality as compared to HCM patients with sinus rhythm in a recent systematic review.¹⁶ Given the high risk of thromboembolism in patients with HCM, the European Society of Cardiology (ESC) guideline recommended anticoagulation for all HCM patients with co-existing AF, irrespective of their CHA₂DS₂-VASC score.^{1,17} Indeed, HCM reflects substrate abnormalities when evaluating the patient with AF, and invariably is associated with heart failure with preserved ejection fraction (HFpEF).¹⁸

Oral anticoagulation (OAC) is associated with markedly reduced pooled incidence of total thromboembolism in patients with HCM compared with the use of antiplatelet therapy or no treatment (9.5% vs 22.1%). Among OACs, the direct oral anticoagulants (DOAC) outperformed Vitamin K antagonists (VKA) in the association with lower thromboembolic event (4.7% vs 8.7%), major bleeding event (3.8% vs 6.8%), and all-cause mortality (4.1% vs 16.1%) among patients with HCM.¹⁹

Various risk factors such as presence of AF, left atrial (LA) size, age, and CHA₂DS₂-VASC score have been identified based on different cohort studies on HCM (see Table 1). Both CHADS₂ and CHA₂DS₂-VASC scores have been applied in cohorts of HCM.^{8,11} In a population-based cohort of 17,371 patients with HCM with absence of AF at baseline, CHA₂DS₂-VASC score 0–2 was associated with 1.5–2 fold increase in ischaemic stroke compared with general population with AF, whereas no significant difference was noted in stroke rate between HCM patients with CHA₂DS₂-VASC score ≥ 3 as compared with control.¹² Other risk scores have been proposed, one incorporated the CHADS₂ score, left ventricular outflow tract

gradient (LVOTG), and presence of permanent AF,⁷ while the HCM Risk-CVA score included parameters such as age, presence of AF, interaction between age and AF, prior thromboembolism, the New York Heart Association Functional classification (NYHA) II or III/IV, LA diameter, vascular disease, maximal wall thickness (MWT) and the square of MWT.⁸ The HCM Risk-CVA score has been validated in a cohort of 417 patients with HCM, results showing limited value for clinical utility¹⁰ (see Table 1).

In this issue of *Hellenic Journal of Cardiology*, Wang et al. presented their study which validated the R-CHA₂DS₂-VASC score in a cohort of 446 patients with HCM.²⁰ The CHA₂DS₂-VASC score (congestive heart failure, hypertension, age ≥ 75 (doubled), diabetes, stroke (doubled), vascular disease, age 65–74, and female sex) is most commonly used in the risk stratification for stroke in AF,²¹ although the female sex (Sc) criterion is a risk modifier rather than a risk factor.²² The R-CHA₂DS₂-VASC score was previously proposed for stroke risk estimation in patients with myocardial infarction, which included additional components such as renal function including blood urea nitrogen (BUN) and estimated glomerular filtration rate (eGFR), performance of a revascularization procedure, and presence of AF on the basis of CHA₂DS₂-VASC score.²³

In this study by Wang et al.,²⁰ a moderate discriminative value in thromboembolism was demonstrated with C-statistic 0.77 (95% confidence interval: 0.65–0.89) using the R-CHA₂DS₂-VASC score. This significant improvement in risk stratification for thromboembolism as compared to previous cohorts using CHA₂DS₂-VASC score^{8,12} is most likely due to the addition of AF into the risk scheme, rather than the letter “R” (renal function). Whereas HCM has been recognized as an independent risk factor for end-stage renal disease,²⁴ there is no evidence supporting reduced renal function as an independent risk factor for thromboembolism in patients with HCM. Also, many of the determinants of renal impairment are represented by the components of CHA₂DS₂-VASC, eg. age, hypertension, diabetes, vascular disease etc. Furthermore, in this study, eGFR 30–59% (16.5% of the cohort) was risk factor for thromboembolism on univariate analysis (only 2.9% of the cohort had eGFR < 30%), and BUN was not a risk factor for thromboembolism. Hence, kidney disease is unlikely to have contributed significantly to the discriminative power of the clinical risk score. Additionally, only 2.5% of the cohort had revascularization to add the additional component in the R-CHA₂DS₂-VASC score.

Clinical risk stratification is an evolving field, and much focus has been directed to improve clinical risk prediction. Given the limitations of clinical risk scores, the aim of clinical risk stratification for thromboembolism has shifted to initially identify the true low-risk patients, which is perhaps especially relevant in HCM. The high-risk group of HCM patients with AF is already advised to be offered anticoagulation and HCM patients at the very

Peer review under responsibility of Hellenic Society of Cardiology.

<https://doi.org/10.1016/j.hjc.2020.11.003>1109-9666/© 2020 Hellenic Society of Cardiology. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Table 1
Risk factors and risk schemes for thromboembolism in hypertrophic cardiomyopathy

Study	No. of patients	Location	Design	Age (mean, years)	Follow-up (median, years)	AF at baseline (%)	Anticoagulation therapy, %	Accumulative TE incidence (95% CI)	Significant risk factors* for TE	Risk models tested
Higashikawa 1997 ⁵	83	Single centre, Japan	Retrospective, longitudinal cohort	55.5	8	22.9	10.8	23% in AF vs 5.9% in non-AF over 5 years	AF, beta-blocker	
Maron 2002 ⁶	900	4 centres in US and Italy	Retrospective, longitudinal cohort	46	7	21	9.1 (in AF group) Unreported figure in non-AF	5.7%	Woman, age, NYHA functional class, AF	
Benchimol Barbosa 2013 ⁷	172	Brazil	Prospective cohort	40 (median)	12.3	Not reported	Not reported	4% per year	CHADS ₂ >1, LVOTG>38 mmHg, permanent AF	New risk scheme: CHADS ₂ >1 (score 2), LVOTG>38 mmHg (score 3), permanent AF (score 3)
Tian 2013 ²⁸	654	Single centre, China	Prospective cohort	50	4.2	17	3	Not reported (in figure)	(In patients without previous stroke): AF and age	
Guttmann 2015 ⁸	4,821	7 European centres	Retrospective, longitudinal cohort	49	6	12.46	9.2	5 year: 2.9% (2.37%–3.48%), 10 year: 6.4% (5.42%–7.53%)		HCM Risk-CVA score): C-statistic 0.75 (0.70–0.80), D-statistic 1.30 (1.05–1.56) CHA ₂ DS ₂ VASc: unsatisfactory stratification on incidence of TE
Haruki 2016 ⁹	593	Single centre, Japan	Prospective cohort	51	10.7	27.3	Not reported	1.0% per year	(In patients without previous AF): Age, enlarged LA	
Zegkos 2017 ²⁹	509	Single centre, Greece	Retrospective, longitudinal cohort	51	9	23.3	15.9	Not reported	LA size (optimal cut-off at 4.2 cm)	
Choi 2018 ¹³	~3,000 (2005)–11,500 (2015)	Korean national health insurance service database	Nationwide, population-based study	61.5	10 (total)	13.39	58 (HCM with AF)	AF-associated stroke: 2.94% per year	(In patients with new onset AF): Sex, age (trend), CHA ₂ DS ₂ -VASc (trend)	
He 2019 ¹⁰	417	Single centre, China	Prospective cohort	55.2	3.5	15.8	8.4	1.6% per year		HCM Risk-CVA score ⁸ C-statistic: 0.67 (0.55–0.79) Subgroup without AF: C-statistic: 0.67 (0.51–0.83) CHADS ₂ score: non-significant predictive accuracy for TE
Hirota 2019 ¹¹	293	Japan, regional HCM register (Kochi Ryoma study)	Prospective cohort	63	6.1	29	27	5.5% over 5 years		
Lin 2019 ¹²	17,371	Taiwan, national health insurance research database	Nationwide, population-based longitudinal study	61	7.3	0 (HCM without AF)	Not reported	0.59% per year for ischaemic stroke	Age, CHA ₂ DS ₂ -VASc, sudden cardiac death	CHA ₂ DS ₂ -VASc: significantly raised stroke rate in HCM with score ≤2 ¹ Similar stroke rate with score ≥3 ¹

HCM Risk-CVA score: consists of age, AF, interaction between age and AF, prior TE, NYHA II or III/IV, LA diameter, vascular disease, MWT, MWT².

CI: confidence interval, HR: hazard ratio, LA: Left atrial size, LVOTG: left ventricular outflow tract gradient, MWT: Maximal wall thickness, NYHA: New York Heart Association Functional classification, TE: thromboembolic event.

* Significant association with thromboembolic event in multivariate analysis.

[†] compared with matched general population with AF.

minimum should score 1 point on the C criterion (due to HFpEF) using the CHA₂DS₂-VASc score, as defined for AF.

Increasingly complex clinical risk scores may improve prediction at least statistically, but this needs to be balanced against simplicity and practicality for used in busy everyday clinical settings. Addition of biomarkers (whether urine, blood or imaging ones) will always improve on clinical risk prediction, again statistically but the clinical difference is marginal, especially in real world clinical practice.²⁵ Many biomarkers are non-specific, being predictive of outcomes beyond those of interest.^{26,27} Indeed, statistical significance is not the same as clinical significance.

Conflict of interest

TP: Consultant for Bayer/Janssen and BMS/Pfizer (no fees). GYHL: Consultant for Bayer/Janssen, BMS/Pfizer, Boehringer Ingelheim, Verseen and Daiichi-Sankyo. Speaker for BMS/Pfizer, Boehringer

Ingelheim, and Daiichi-Sankyo. No fees are directly received personally.

References

1. Elliott PM, Anastakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). *Eur Heart J*. 2014;35(39):2733–2779.
2. Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. *J Am Coll Cardiol*. 2015;65(12):1249–1254.
3. Lorenzini M, Anastasiou Z, O'Mahony C, et al. Mortality Among Referral Patients With Hypertrophic Cardiomyopathy vs the General European Population. *JAMA Cardiol*. 2020;5(1):73–80.
4. Liu Q, Li D, Berger AE, Johns RA, Gao L. Survival and prognostic factors in hypertrophic cardiomyopathy: a meta-analysis. *Sci Rep*. 2017;7(1):11957.
5. Higashikawa M, Nakamura Y, Yoshida M, Kinoshita M. Incidence of ischemic strokes in hypertrophic cardiomyopathy is markedly increased if complicated by atrial fibrillation. *Jpn Circ J*. 1997;61(8):673–681.

6. Maron BJ, Olivetto I, Bellone P, et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. *J Am Coll Cardiol*. 2002;39(2):301–307.
7. Benchimol Barbosa PR, Barbosa EC, Bomfim AS, Ribeiro RL, Boghossian SH, Kantharia BK. A practical score for risk stratification of embolic stroke in hypertrophic cardiomyopathy. *Eur Heart J*. 2013;34(suppl_1):P2969.
8. Guttman OP, Pavlou M, O'Mahony C, et al. Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA). *Eur J Heart Fail*. 2015;17(8):837–845.
9. Haruki S, Minami Y, Hagiwara N. Stroke and Embolic Events in Hypertrophic Cardiomyopathy: Risk Stratification in Patients Without Atrial Fibrillation. *Stroke; a journal of cerebral circulation*. 2016;47(4):936–942.
10. He S, Wang Z, Cheem TH, Liao H, Chen X, He Y. External Validation of the Model of Thromboembolic Risk in Hypertrophic Cardiomyopathy Patients. *Can J Cardiol*. 2019;35(12):1800–1806.
11. Hirota T, Kubo T, Baba Y, et al. Clinical Profile of Thromboembolic Events in Patients With Hypertrophic Cardiomyopathy in a Regional Japanese Cohort - Results From Kochi RYOMA Study. *Circ J*. 2019;83(8):1747–1754.
12. Lin TT, Sung YL, Ko TY, et al. Risk of ischemic stroke in patients with hypertrophic cardiomyopathy in the absence of atrial fibrillation - a nationwide cohort study. *Aging (Albany NY)*. 2019;11(23):11347–11357.
13. Choi YJ, Choi EK, Han KD, et al. Temporal trends of the prevalence and incidence of atrial fibrillation and stroke among Asian patients with hypertrophic cardiomyopathy: A nationwide population-based study. *Int J Cardiol*. 2018;273:130–135.
14. Guttman OP, Rahman MS, O'Mahony C, Anastasakis A, Elliott PM. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. *Heart*. 2014;100(6):465–472.
15. Olivetto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. *Circulation*. 2001;104(21):2517–2524.
16. Alphonse P, Virk S, Collins J, et al. Prognostic impact of atrial fibrillation in hypertrophic cardiomyopathy: a systematic review. *Clin Res Cardiol*. 2020.
17. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). *Eur Heart J*. 2020.
18. Potpara TS, Lip GYH, Blomstrom-Lundqvist C, et al. The 4S-AF Scheme (Stroke Risk; Symptoms; Severity of Burden; Substrate): A Novel Approach to In-Depth Characterization (Rather than Classification) of Atrial Fibrillation. *Thromb Haemostasis*. 2020.
19. Lozier MR, Sanchez AM, Lee JJ, Donath EM, Font VE, Escolar E. Thromboembolic Outcomes of Different Anticoagulation Strategies for Patients with Atrial Fibrillation in the Setting of Hypertrophic Cardiomyopathy: A Systematic Review. *J Atr Fibrillation*. 2019;12(4):2207.
20. Wang Z, Liao H, He S, Chen X. Performance and validation of R-CHA₂DS₂-VASC score for thromboembolism in patients with hypertrophic cardiomyopathy. *Hellenic J Cardiol*. 2019.
21. Lip GY, Nieuwlaet R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. *Chest*. 2010;137(2):263–272.
22. Nielsen PB, Overvad TF. Female Sex as a Risk Modifier for Stroke Risk in Atrial Fibrillation: Using CHA₂DS₂-VASC versus CHA₂DS₂-VA for Stroke Risk Stratification in Atrial Fibrillation: A Note of Caution. *Thromb Haemostasis*. 2020;120(6):894–898.
23. Barra S, Almeida I, Caetano F, et al. Stroke prediction with an adjusted R-CHA₂DS₂-VASC score in a cohort of patients with a Myocardial Infarction. *Thromb Res*. 2013;132(2):293–299.
24. Lee H, Han K, Park JB, et al. Risk of end-stage renal disease in patients with hypertrophic cardiomyopathy: A nationwide population-based cohort study. *Sci Rep*. 2019;9(1):14565.
25. Rivera-Caravaca JM, Marín F, Vilchez JA, et al. Refining Stroke and Bleeding Prediction in Atrial Fibrillation by Adding Consecutive Biomarkers to Clinical Risk Scores. *Stroke*. 2019;50(6):1372–1379.
26. Esteve-Pastor MA, Roldán V, Rivera-Caravaca JM, Ramírez-Macías I, Lip GYH, Marín F. The Use of Biomarkers in Clinical Management Guidelines: A Critical Appraisal. *Thromb Haemostasis*. 2019;119(12):1901–1919.
27. Camelo-Castillo A, Rivera-Caravaca JM, Marín F, Vicente V, Lip GYH, Roldán V. Predicting Adverse Events beyond Stroke and Bleeding with the ABC-Stroke and ABC-Bleeding Scores in Patients with Atrial Fibrillation: The Murcia AF Project. *Thromb Haemostasis*. 2020;120(8):1200–1207.
28. Tian T, Wang Y, Sun K, et al. Clinical profile and prognostic significance of atrial fibrillation in hypertrophic cardiomyopathy. *Cardiology*. 2013;126(4):258–264.
29. Zegkos T, Efthimiadis GK, Parcharidou DG, et al. Atrial fibrillation in hypertrophic cardiomyopathy: A turning point towards increased morbidity and mortality. *Hellenic J Cardiol*. 2017;58(5):331–339.

Juqian Zhang

Liverpool Centre for Cardiovascular Science, University of Liverpool
and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom

Tatjana Potpara

School of Medicine, University of Belgrade, Belgrade, Serbia

Gregory YH. Lip*

Liverpool Centre for Cardiovascular Science, University of Liverpool
and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom

School of Medicine, University of Belgrade, Belgrade, Serbia

Department of Clinical Medicine, Aalborg University, Aalborg,
Denmark

* Corresponding author. Gregory YH Lip, MD, FRCP, Liverpool
Centre for Cardiovascular Science, University of Liverpool and
Liverpool Heart & Chest Hospital, Liverpool, United Kingdom
E-mail address: Gregory.Lip@liverpool.ac.uk (G.YH. Lip).

Available online 6 November 2020